AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02491021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Class
Description: A 6 week programme of exercise and education in an out patient setting
Study NCT03985852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Directed Standard of Care
Description: The pre-test genetic counseling visit will be conducted through access to an automated genetics education assistant accessed through the patient portal. The automated approach will address all the components of the pre-test counseling and contains content designed by the genetic counselors at the University of Utah and NYU. Patients will have the option to contact genetic counselors through the patient portal, by phone, or in person but this will not be required. All results will be reviewed by a genetic counselor. Negative results will be returned by the automated genetics education assistant. Genetic counselors will return results for pathogenic variants and variants of uncertain significance via phone.
Study NCT04596631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
Study NCT04596631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo treatment for 52 weeks.
Study NCT03002064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
Study NCT03002064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
Study NCT03002064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
Study NCT03002064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
Study NCT00859651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.
Study NCT00859651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsule
Description: Matching placebo capsules
Study NCT02568631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serious game JeStiMulE
Description: The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.
Study NCT02568631 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control video game
Description: The patients will play 6 sessions of one hour with the control video game
Study NCT00451165 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic colorectal surgery
Description: laparoscopic colorectal surgery
Study NCT03654131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MWA
Description: Patients are allocated to one of the two arms in a 1:1 randomization
Study NCT03654131 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Patients are allocated to one of the two arms in a 1:1 randomization
Study NCT02608697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT03407690 — intervention group
Intervention type: OTHER
Intervention: nasal swab
Description: collection of nasal swab to allow carriage of pneumococci to be assessed
Study NCT00775814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan and Hydrochlorothiazide
Description: Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
Study NCT00775814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCT)
Description: Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
Study NCT01806584 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SRM003
Description: One time implant (3 SRM003 pieces) on surgery day.
Study NCT01806584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Participating Site's standard practice
Description: Subjects will receive sites' standard practice treatment during the surgical procedure
Study NCT01445808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodynamic Motivation and Training Program (PMT)
Description: The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
Study NCT03492762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu-DOTA-ECL1i
Description: Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.
Study NCT01445808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice in Exercise Training (+Ex)
Description: Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
Study NCT01445808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: Usual care by family doctor, cardiologist
Study NCT01807650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10, non-adhesive wound dressing
Description: 1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
Study NCT01807650 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-adhesive wound dressing only
Description: Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
Study NCT03904030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation with or without Anti-Gravity Treadmill
Description: The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
Study NCT03904030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation with or without Anti-Gravity Treadmill
Description: The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
Study NCT04781361 — intervention group
Intervention type: DRUG
Intervention: Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose
Description: Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
Study NCT04781361 — intervention group
Intervention type: DRUG
Intervention: Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L
Description: Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride \< 130 mmol/L
Study NCT04798443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subureteral endoscopic Injection of Dextranomer/Hyaluronic acid (Dexell)
Description: The subureteral endoscopic injection was done under general anesthesia. the investigators used the subureteral injection technique (STING), as described by O'Donnell and Puri. The volume of Dexell was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
Study NCT04798443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open ureteral reimplantation (Lich-Gregoir)
Description: The juxtavesical ureter is dissected by open surgery and a submucosal groove is created extending laterally from the ureteral hiatus along the course of the ureter. The ureter is placed in the groove and the detrusor is closed over the ureter with ureteric stent fixation for 21 days. the surgical wound is closed in layers. Urethral catheter for bladder drainage for 3-5 days.
Study NCT02609646 — intervention group
Intervention type: DRUG
Intervention: Linezolid
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
Study NCT02609646 — intervention group
Intervention type: DRUG
Intervention: Meropenem
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
Study NCT02609646 — intervention group
Intervention type: DRUG
Intervention: Piperacillin-tazobactam combination product
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
Study NCT02609646 — intervention group
Intervention type: DRUG
Intervention: Vancomycin
Description: Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
Study NCT04444635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plan Block+ Fentanyl infusion
Description: After induction of anesthesia, the patients will be put on the lateral position with the diseased side up. A linear ultrasound transducer will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage.~Then counting down ribs till the fifth rib will be identified in the mid-axillary line. The following muscles will be identified overlying the fifth rib: the latissimus dorsi (superficial and posterior),teres major (superior) and serratus muscles (deep and inferior). Under complete sterile conditions, the needle (25 G needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. Then, 2 mg/kg of 0.25% bupivacaine will be injected with continuous ultrasound guidance. In addition to continuous fentanyl infusion
Study NCT04444635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Continuous fentanyl infusion throughout the surgical procedure.
Study NCT04539314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%
Study NCT04539314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine o.5 μg
Description: We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 0.5 μg / kg
Study NCT04539314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1 μg
Description: We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 1 μg / kg
Study NCT01905644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineal ultrasound
Description: Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
Study NCT00740558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Activator methods technique
Description: Chiropractic adjustment by a manually assisted mechanical force
Study NCT00740558 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Activator methods technique
Description: Chiropractic adjustment by a manually assisted mechanical force
Study NCT00740558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chiropractic adjustment
Description: Lumbar roll according to the Diversified technique of chiropractic adjusting
Study NCT00740558 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Traditional chiropractic adjustment
Description: Lumbar roll according to the Diversified technique of chiropractic adjusting
Study NCT02268695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02268695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT04065971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LHERP®
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study NCT04065971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study NCT04357665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral TAPP Repair
Description: laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
Study NCT02268695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracile
Study NCT02268695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02268695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Study NCT02268695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT02268695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granulocyte colony-stimulating factor (G-CSF)
Study NCT03080116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509
Description: 240mg/day (4x60mg tablets, Oral administration: OS)
Study NCT03080116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: 1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
Study NCT03080116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: 1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
Study NCT03080116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4 tablets, per OS
Study NCT04357665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open PP Repair
Description: Open pre-peritoneal repair using single mesh fixed by sutures
Study NCT04357665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Lichtenstein Repair
Description: Bilateral Lichtenstein Repair using 2 separate meshes fixed by sutures
Study NCT04370756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice
Description: Participants randomly assigned to the EX + BR group will consume 140 mL beetroot juice containing approximately 12 mmol of nitrate 3 hours prior to the supervised exercise training component.
Study NCT04370756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Participants will perform 8 weeks of supervised exercise training at a frequency of 3x per week.
Study NCT04370756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Participants will perform 8 weeks of supervised exercise training at a frequency of 3x per week.
Study NCT02985983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Administered Brodalumab by subcutaneous (SC) injection until week 66.
Study NCT02985983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Placebo by subcutaneous (SC) injection until week 16. Administered Brodalumab by SC injection from week 17 until week 66.
Study NCT04370054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Description: Single IV infusion
Study NCT03260582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifePod®
Description: The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
Study NCT02462525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-838
Description: Varying doses of ABBV-838
Study NCT02462525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Administered orally per the label.
Study NCT02462525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally per the label.
Study NCT04676451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femto-AK
Description: Astigmatic Keratotomy / Arcuate Incisions for the correction of astigmatism
Study NCT02043028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest compression with a step stool
Description: Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes
Study NCT02043028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest compression with a kneeling stool
Description: Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
Study NCT04327141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-IF
Description: Protein pacing and intermittent fasting
Study NCT04327141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HH
Description: Heart Healthy
Study NCT02269514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand Cigarette
Description: combustible cigarette brand style smoked most frequently by subject
Study NCT02269514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #1
Description: VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
Study NCT02269514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #2
Description: VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
Study NCT00794040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add-on citalopram following optimized methylphenidate
Description: After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
Study NCT00794040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Add-on placebo following optimized methylphenidate
Description: After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
Study NCT01154348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-707106
Description: Tablet, taken once daily with morning meal
Study NCT01154348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, taken once daily with morning meal